Christopher Heaphy PhD

Assistant Professor, Hematology & Medical Oncology

Graduate Faculty (Primary Mentor of Grad Students)

650 Albany St | (617) 638-7536
Christopher Heaphy

Hematology & Medical Oncology


BU-BMC Cancer Center

Evans Center for Interdisciplinary Biomedical Research


Dr. Christopher Heaphy is a cancer biologist that has been conducting basic and translational studies focused on elucidating the role of telomere alterations across a range of cancer types (e.g. prostate, breast, brain, pancreatic, ovarian). Overall, his research program uses a combination of tissue-based, cell-based, and molecular approaches to study normal and abnormal telomere biology as it relates to cancer initiation and progression, with a particular interest in the Alternative Lengthening of Telomeres (ALT) phenotype – a telomerase-independent telomere maintenance mechanism. In addition, his laboratory focuses on how these findings may be readily translated into accurately predicting cancer risk, early detection, prognosis, and potential response to targeted therapies. Dr. Heaphy received his Ph.D. from the University of New Mexico School of Medicine and did his postdoctoral training at the Johns Hopkins University School of Medicine. He is currently affiliated with Boston Medical Center and is a member of the Boston University-Boston Medical Center (BU-BMC) Cancer Center.


Biomedical Sciences, PhD, University of New Mexico School of Medicine, 2008

Biology/Biochemistry, BS, University of New Mexico, 2003


Published on 7/21/2022

Heaphy CM, Singhi AD. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol. 2022 Nov; 129:11-20. PMID: 35872157.

Published on 7/14/2022

Heaphy CM, Joshu CE, Barber JR, Davis C, Lu J, Zarinshenas R, Giovannucci E, Mucci LA, Stampfer MJ, Han M, De Marzo AM, Lotan TL, Platz EA, Meeker AK. The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. J Pathol Clin Res. 2022 Sep; 8(5):481-491. PMID: 35836303.

Published on 6/19/2022

Yuan M, Eberhart CG, Pratilas CA, Blakeley JO, Davis C, Stojanova M, Reilly K, Meeker AK, Heaphy CM, Rodriguez FJ. Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. Cancers (Basel). 2022 Jun 19; 14(12). PMID: 35740680.

Published on 4/14/2022

Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2022 Apr 14; 28(8):1737. PMID: 35419593.

Published on 4/11/2022

Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015. PMID: 35403746.

Published on 1/24/2022

Lally SE, Milman T, Orloff M, Dalvin LA, Eberhart CG, Heaphy CM, Rodriguez FJ, Lin CC, Dockery PW, Shields JA, Shields CL. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology. 2022 Jun; 129(6):679-693. PMID: 35085662.

Published on 12/18/2021

Dreijerink KM, Hackeng WM, Singhi AD, Heaphy CM, Brosens LA. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. J Pathol. 2022 02; 256(2):143-148. PMID: 34750813.

Published on 8/10/2021

Shrestha E, Coulter JB, Guzman W, Ozbek B, Hess MM, Mummert L, Ernst SE, Maynard JP, Meeker AK, Heaphy CM, Haffner MC, De Marzo AM, Sfanos KS. Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proc Natl Acad Sci U S A. 2021 08 10; 118(32). PMID: 34341114.

Published on 7/9/2021

Heaphy CM, VandenBussche CJ. Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathol. 2021 11; 129(11):841-843. PMID: 34242496.

Published on 6/15/2021

Kang HJ, Oh JH, Kim YW, Kim W, An J, Sung CO, Kim J, Shim JH, Hwang S, Yu E, Heaphy CM, Hong SM. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver Int. 2021 10; 41(10):2499-2510. PMID: 34036718.

View full list of 98 publications.